As discussed earlier, HPX has been evaluated as a therapeutic agent in various heme overload diseases, including SCD, blood transfusions, sepsis, malaria, hemolytic-uremic syndrome, ICH, and SAH. The gene discussed is HPX; the disease is hemolytic-uremic syndrome.